Raja B Khan1, Maha Bano2, Fang Wang3, Pan Haitao3, Anthony Christensen4, Jessica Smith1, Andrea Simmons1, Zsila S Sadighi5. 1. Division of Neurology, St Jude Children's Research Hospital, Memphis, Tennessee. 2. Department of Pediatrics, University of Tennessee, Memphis, Tennessee. 3. Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee. 4. Pharmaceutical Services, St Jude Children's Research Hospital, Memphis, Tennessee. 5. Department of Neuro-Oncology, MD Anderson Cancer Center, Houston, Texas.
Abstract
INTRODUCTION: Children with brain tumors may develop inattention, slow processing, and hypersomnia. Stimulant medications improve these problems, but their effect on growth, heart rate, and blood pressure (BP) are inadequately explored. PROCEDURE: We retrospectively studied children with brain tumors treated at our institution that had data available for 1 year pre and 2 years on stimulant treatment. Tumor location, gender, radiation treatment (RT), age at RT, drug type, and hormone therapy were variables of interest. RESULTS: We identified 65 children (35 males) that fulfilled eligibility criteria. Focal RT was utilized in 58; 11 additionally had whole brain RT; and seven received no RT. Thirty were treated for hypersomnia and inattention, eight for hypersomnia alone, and rest for inattention. Modafinil was the first drug in 18 (27.7%), and methylphenidate in the others. Forty-seven (72.3%), 45 (69.2%), and 49 (75.4%) were on thyroxine, cortisone, and growth hormones, respectively. There was no difference in pre- and post-stimulant body mass index (BMI), heart rate, and BP. There was also no difference between modafinil and methylphenidate groups. Rate of height acquisition slowed on stimulants (P = .0096). Thyroxine treatment correlated with increase in BMI after stimulants (P = .04). Younger age (P = .0003) and higher prestimulant BMI (P = .0063) correlated with increased heart rate on stimulants, while higher age at RT (P =.016) correlated with elevated systolic BP on stimulants. No associations were found with height acquisition and diastolic BP. CONCLUSION: Stimulants are well tolerated by children with brain tumors that are appropriately managed for endocrine deficiencies, but may reduce the trajectory of height attainment.
INTRODUCTION: Children with brain tumors may develop inattention, slow processing, and hypersomnia. Stimulant medications improve these problems, but their effect on growth, heart rate, and blood pressure (BP) are inadequately explored. PROCEDURE: We retrospectively studied children with brain tumors treated at our institution that had data available for 1 year pre and 2 years on stimulant treatment. Tumor location, gender, radiation treatment (RT), age at RT, drug type, and hormone therapy were variables of interest. RESULTS: We identified 65 children (35 males) that fulfilled eligibility criteria. Focal RT was utilized in 58; 11 additionally had whole brain RT; and seven received no RT. Thirty were treated for hypersomnia and inattention, eight for hypersomnia alone, and rest for inattention. Modafinil was the first drug in 18 (27.7%), and methylphenidate in the others. Forty-seven (72.3%), 45 (69.2%), and 49 (75.4%) were on thyroxine, cortisone, and growth hormones, respectively. There was no difference in pre- and post-stimulant body mass index (BMI), heart rate, and BP. There was also no difference between modafinil and methylphenidate groups. Rate of height acquisition slowed on stimulants (P = .0096). Thyroxine treatment correlated with increase in BMI after stimulants (P = .04). Younger age (P = .0003) and higher prestimulant BMI (P = .0063) correlated with increased heart rate on stimulants, while higher age at RT (P =.016) correlated with elevated systolic BP on stimulants. No associations were found with height acquisition and diastolic BP. CONCLUSION: Stimulants are well tolerated by children with brain tumors that are appropriately managed for endocrine deficiencies, but may reduce the trajectory of height attainment.
Authors: Laurence L Greenhill; James M Swanson; Lily Hechtman; James Waxmonsky; L Eugene Arnold; Brooke S G Molina; Stephen P Hinshaw; Peter S Jensen; Howard B Abikoff; Timothy Wigal; Annamarie Stehli; Andrea Howard; Michael Hermanussen; Tomasz Hanć Journal: J Am Acad Child Adolesc Psychiatry Date: 2019-08-15 Impact factor: 8.829
Authors: Heather M Conklin; Joanne Lawford; Bruce W Jasper; E Brannon Morris; Scott C Howard; Susan W Ogg; Shengjie Wu; Xiaoping Xiong; Raja B Khan Journal: Pediatrics Date: 2009-07 Impact factor: 7.124
Authors: James G Waxmonsky; William E Pelham; Adriana Campa; Daniel A Waschbusch; Tan Li; Rebecca Marshall; Lysett Babocsai; Hugh Humphery; Elizabeth Gnagy; James Swanson; Tomasz Hanć; Negar Fallahazad; William E Pelham Journal: J Am Acad Child Adolesc Psychiatry Date: 2019-08-29 Impact factor: 8.829
Authors: Belinda N Mandrell; Kayla LaRosa; Donna Hancock; Mary Caples; April Sykes; Zhaohua Lu; Merrill S Wise; Raja B Khan; Thomas E Merchant; Valerie McLaughlin-Crabtree Journal: J Neurooncol Date: 2020-04-28 Impact factor: 4.130
Authors: Wassim Chemaitilly; Laurie E Cohen; Sogol Mostoufi-Moab; Briana C Patterson; Jill H Simmons; Lillian R Meacham; Hanneke M van Santen; Charles A Sklar Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Bruce W Jasper; Heather M Conklin; Joanne Lawford; E Brannon Morris; Scott C Howard; Shengjie Wu; Xiaoping Xiong; John Shelso; Raja B Khan Journal: Pediatr Blood Cancer Date: 2009-01 Impact factor: 3.167
Authors: Edwin F Liang; Samuel Z Lim; Wilson W Tam; Cyrus S Ho; Melvyn W Zhang; Roger S McIntyre; Roger C Ho Journal: Int J Environ Res Public Health Date: 2018-08-20 Impact factor: 3.390